KAIJU BIO
Target Everything.
Building a next-generation platform that renders previously intractable scales of therapeutic discovery and delivery accessible across targets beyond the reach of antibodies and small molecules.
Technology
Kaiju Bio is building an AI enabled platform for ultra large scale aptamer discovery and targeted molecular delivery.
The platform applies machine learning guided library design and high-throughput screening in human cells to explore extremely large, rationally designed and manufactured nucleic acid sequences for functional binding and delivery performance in physiologically relevant conditions.
Learning from experimental screening data guides iterative refinement of libraries and prioritization of candidates across design cycles, enabling generalization across biological targets that are difficult or inaccessible to conventional antibodies and small molecules.
Learn more (in press, Nature Biotech): preprint link
With Support From
Team
Cameron Gardner, PhD — Founder & CEO
Mia Rosenfeld, PhD
Winston Tang